The adverse effects of abnormalities in SLF2 and SMC5.
Image Credit: KyotoU / Sho Shibata
Scientific Frontline: Extended "At a Glance" Summary: SLF2 and SMC5 Dysfunction in Bone Marrow Disorders
The Core Concept: Inherited genetic abnormalities in the SLF2 and SMC5 genes have been identified as a previously unrecognized cause of inherited bone marrow failure syndrome (IBMFS) and a driver of predisposition to myelodysplastic syndromes (MDS).
Key Distinction/Mechanism: Mutations in SLF2 and SMC5, genes originally linked to the neurodevelopmental disorder Atelis syndrome, induce the activation of the tumor suppressor p53 protein, which subsequently leads to the premature aging and failure of hematopoietic stem cells.
Major Frameworks/Components:
- Utilization of patient-derived induced pluripotent stem cell (iPSC) lines carrying pathogenic SLF2 variants.
- Application of CRISPR-Cas9 gene editing to generate genetically corrected isogenic lines.
- In vitro and in vivo differentiation and evaluation of hematopoietic progenitor cells.
- Observation of p53 protein activation directly linked to premature hematopoietic stem cell aging.
Branch of Science: Molecular Genetics, Hematology, Oncology, and Cellular Biology.
Future Application: This research provides a foundation for identifying the underlying genetic causes in previously unexplained cases of IBMFS and MDS in pediatric patients, paving the way for novel diagnostic tools and therapeutic strategies utilizing targeted gene correction.
Why It Matters: By successfully reversing cellular abnormalities through the correction of SLF2 variants in patient-derived iPSCs, researchers provided direct evidence of causality, fundamentally linking a known neurodevelopmental genetic defect to critical failures in blood cell production and cancer predisposition.
Inherited bone marrow failure syndrome, or IBMFS, describes a group of disorders in which inherited genetic abnormalities impair the bone marrow's ability to produce sufficient healthy blood cells. Patients with these disorders are also at increased risk of developing myelodysplastic syndromes—MDS—a group of blood cancers in which the bone marrow produces excess abnormal blood cells and insufficient healthy ones.
When young patients are diagnosed with either condition, an underlying germline genetic abnormality is generally suspected as the cause. The genetic basis and mechanisms of these diseases remain unknown in many patients, but advances in genomic analysis are identifying an increasing number of causative genes.
Recently, germline variants in the genes SLF2 and SMC5 were reported to cause Atelis syndrome, a neurodevelopmental disorder frequently accompanied by blood abnormalities. During a follow-up with syndrome patients, a team of researchers at Kyoto University found that some had developed MDS at a young age and that clinical features of IBMFS were evident. The team hypothesized that the abnormalities in SLF2 and SMC5 represent a previously unrecognized cause of IBMFS and indicate a predisposition to MDS.
The scientists established iPS cell lines from a patient carrying pathogenic SLF2 variants and used these to generate genetically corrected isogenic lines with CRISPR-Cas9 gene editing. They then differentiated the hematopoietic progenitor cells, which produce mature blood cells, and evaluated the effects of the SLF2 variants on hematopoietic stem cell function both in vitro and in vivo.
The team's results confirm that the germline mutations in SLF2 and SMC5 cause both IBMFS and a predisposition to MDS. Furthermore, these mutations induce activation of the cancer-fighting p53 protein and lead to premature hematopoietic stem cell aging.
"We were intrigued to find that genes originally linked to a neurodevelopmental disorder also play a critical role in maintaining hematopoietic stem cell function and that their disruption predisposes individuals to MDS," said first author Sho Shibata.
These findings identify the causative genes behind IBMFS and germline predisposition to MDS and provide new insights into how defects in SLF2 and SMC5 promote hematopoietic stem cell aging. These results also give researchers clues for identifying the genetic causes of unexplained IBMFS and MDS in young patients.
"It is particularly exciting to see that correcting the SLF2 variants in patient-derived iPSCs reversed the cellular abnormalities, providing direct evidence that these variants cause bone marrow failure," said corresponding author Kazuhisa Chonabayashi. "We hope these findings will improve our understanding of previously unexplained cases and pave the way for new therapeutic strategies."
Published in journal: Leukemia
Authors: Sho Shibata, Kazuhisa Chonabayashi, Hirofumi Nakamura, Yasuko Matsumura, Hiroki Kawahara, Yoshio Okamoto, Shohei Yamamoto, Misato Nishikawa, Yotaro Ochi, Yuri Uchiyama, Yukiko Oh, Akitsu Hotta, Kenta Masuda, Naomichi Matsumoto, Seishi Ogawa, Yoshinori Yoshida, and Akifumi Takaori-Kondo
Source/Credit: Kyoto University
Edited by: Scientific Frontline
Reference Number: gen081026_01
